Krystal Biotech, Inc. KRYS

345.82 0.86 0.25% as of 25 Sep
Market cap
$10.2B
P/E
41.9×
Growth Flags show if company had growth for consecutive years

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
389.13 290.52 50.70 — — — — — — —
Revenue Growth
33.94% 473.02% — — — — — — — —
Cost of Revenue
23.05 20.06 3.09 4.06 2.77 1.85 0.97 0.14 0.02 0.00
Gross Profit
366.08 270.45 47.61 (4.05) (2.77) (1.85) (0.97) (0.14) (0.02) 0.00
R&D Expenses
58.05 53.58 46.43 42.46 27.88 17.94 15.62 7.76 3.21 0.74
SG&A Expenses
146.74 113.63 98.29 77.74 40.39 15.06 6.47 4.16 1.56 0.40
Operating Income
161.30 65.75 (109.62) (145.20) (68.27) (33.00) (22.08) (11.92) (4.77) (1.14)
Non-operating Income/Expense
28.18 29.61 122.51 5.22 (1.29) 0.83 2.99 1.03 (3.15) (0.01)
Non-operating Interest Expenses
— — — 5.22 1.49 0.83 2.99 1.03 3.15 0.01
EBT
189.47 95.36 12.90 (139.97) (69.57) (32.17) (19.09) (10.89) (7.92) (1.15)
Income Tax Provision
(15.36) 6.20 1.97 — — — — — — —
Income after Tax
204.83 89.16 10.93 (139.97) (69.57) (32.17) (19.09) (10.89) (7.92) (1.15)
Net Income Common
204.83 89.16 10.93 (139.97) (69.57) (32.17) (19.09) (10.89) (7.92) (1.15)
EPS (Basic)
7.08 3.12 0.40 (5.49) (3.13) (1.71) (1.20) (0.97) (1.48) (1.31)
EPS (Diluted)
6.84 3.00 0.39 (5.49) (3.13) (1.71) (1.20) (0.97) (1.48) (1.31)
Shares (Basic, Weighted)
28.94 28.59 27.15 25.49 22.20 18.79 15.90 11.20 5.36 0.88
Shares (Diluted, Weighted)
29.95 29.74 27.75 25.49 22.20 18.79 15.90 11.20 5.36 0.88
Gross Margin
94.08% 93.09% 93.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
41.45% 22.63% (216.21%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBT margin
48.69% 32.82% 25.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Profit Margin
52.64% 30.69% 21.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Margin
48.66% 41.02% (1.19%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA
167.85 72.46 (103.71) (141.81) (65.51) (31.15) (20.99) (11.77) (4.75) (1.14)
EBIT
161.30 65.75 (109.62) (145.20) (68.27) (33.00) (22.08) (11.92) (4.77) (1.14)
Income from Continuous Operations
204.83 89.16 10.93 (139.97) (69.57) (32.17) (19.09) (10.89) (7.92) (1.15)
Consolidated Net Income/Loss
204.83 89.16 10.93 (139.97) (69.57) (32.17) (19.09) (10.89) (7.92) (1.15)
EPS (Basic, from Continuous Ops)
7.08 3.12 0.40 (5.49) (3.13) (1.71) (1.20) (0.97) (1.48) (1.31)
EPS (Basic, Consolidated)
7.08 3.12 0.40 (5.49) (3.13) (1.71) (1.20) (0.97) (1.48) (1.31)
EPS (Diluted, from Cont. Ops)
6.84 3.00 0.39 (5.49) (3.13) (1.71) (1.20) (0.97) (1.48) (1.31)
Shares (Diluted, Average)
29.95 29.74 27.75 25.49 22.20 18.79 15.90 11.20 5.36 —
EPS (Diluted, Consolidated)
6.84 3.00 0.39 (5.49) (3.13) (1.71) (1.20) (0.97) (1.48) (1.31)
EBITDA Margin
43.13% 24.94% (204.55%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Margin
51.62% 42.48% (175.16%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Fold the line items

In millions of $ except per-share values · columns are period end dates